The many CCR5 mAbs have been an abject failure for most of

New Post Public Reply Private Reply Replies (3) Message Board
Rubraquercus Doctor580 #27035
646
The many CCR5 mAbs have been an abject failure for most of the iterations, and there have been many iterations. The vast majority were abandoned many many years ago. Simple truth. I suspect the folks at the FDA have been there, done that, and have the t-shirts to prove it. They are likely just rolling their eyes when someone claims X from yet another from an old story.

I am not suggesting it does not work, it is an uphill climb many have abandoned....

From 2007 era

<<Six mouse anti-human CCR5 monoclonal antibodies (mAbs) that showed potent antiviral activities were identified from over 26,000 mouse hybridomas. The epitopes for these mAbs were determined by using various CCR5 mutants, including CCR5/CCR2B chimeras. One mAb, ROAb13, was found to bind to a linear epitope in the N terminus of CCR5. Strikingly, the other five mAbs bind to epitopes derived from extracellular loop 2 (ECL2).

Three CCR5 mAbs, 2D7, PRO 140 (CYDY), and mAb004, that showed potent antiviral activities are currently in development as potential inhibitors of HIV entry.

The ECL2-recognizing mAbs can be divided into three classes based on the regions from where their epitopes derive. mAbs in the first class bind exclusively to ECL2A. 2D7 is the first such antibody reported whose epitope has been mapped to K171/E172. The novel mAbs ROAb10 and ROAb51 also fall into this class. A few mAbs can be classified into the second class, which recognize epitopes in ECL2B (mainly from Tyr184 to Phe189) (25). The third class of mAbs recognize epitopes derived primarily from ECL2A but also from ECL2B or other domains. mAb PRO 140 falls into this class, because it requires Arg168 in ECL2A and Asp2 in the Nt (30). The novel mAbs ROAb12, ROAb14, and ROAb18 described here also belong to this class. These three mAbs use epitopes from both ECL2A and ECL2B. The third class of mAbs exhibited the most potent antiviral activities, followed by the first class. These data suggest that ECL2A provides the crucial components of the epitopes for CCR5 mAbs with highly potent antiviral activities.


In summary, by screening over 26,000 hybridomas, we found about 400 clones that showed specific binding to CCR5 as demonstrated by cell-based ELISA. However, out of these 400 clones, only 7 showed anti-HIV activity . Furthermore, only six mAb clones showed antiviral potency equal to or better than that of the control mAb 2D7, sufficient for being clinical drug candidates. Out of these six mAbs, except for one mAb, ROAb13, which recognizes a linear epitope residing in the Nt of CCR5, all other five mAbs recognize epitopes derived from ECL2. Besides, the control mAb 2D7, which is in preclinical development as an HIV entry inhibitor, also recognizes a similar epitope in ECL2. In addition, two out of three key residues (Arg168 and Tyr176) that are required for binding by the highly potent CCR5 mAb PRO 140 are located in ECL2. Therefore, based on these data, we hypothesize that CCR5 ECL2 contains the dominant epitopes for potent anti-HIV mAbs.

https://aac.asm.org/content/51/4/1386

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Zensar’s AI Forum Puts Operations Before the AI Hype

Updated Category News Views 47

Johannesburg’s AI conversation seems to be shedding its costume jewelry at last. Zensar’s invitation-only CIS Converge 2026 forum, held on November 20, put the attention where it belongs: not on breathless demos, but on whether companies can turn AI into sturdier operations, better customer experiences, and something resembling a measurable return. That is a healthier...

Continue Reading
Lennar Lawsuit Puts Land-Light Claims Under a Microscope

Updated Category News Views 142

Three ugly selloffs, a murky land-bank story, and a fresh securities complaint have turned Lennar into the sort of holding that makes shareholders reread every footnote. The lawsuit is not a verdict, and the allegations remain unproven, but the timeline is nasty enough that investors in NYSE:LEN should not shrug it off as ordinary housing-cycle turbulence. The Dates...

Continue Reading
Anduin Opens Its Investor Portal Beyond Early Users

Updated Category News Views 30

Private-market paperwork has long been a swamp of portals, PDFs, email chains, and somebody chasing down a wire change at the worst possible moment. Anduin is taking a swing at that mess by opening its Investor Portal to all customers after building it with leading asset managers and operating it with their investors. The pitch is sensible: give limited partners one...

Continue Reading
Yangtze Documentary Frames a Decade of Economic Change

Updated Category News Views 54

A fish, a kilowatt-hour, a microchip, and a shipping container walk into the same economic story—well, not literally, thank goodness—and that is the unusual wager behind CCTV4’s upcoming Our Home, Our Yangtze. Announced in Beijing on November 19, 2026, the four-part documentary aims to recount a decade of change across the Yangtze River Economic Belt without leaning...

Continue Reading
Intel Investors Face January 12 Lead Plaintiff Deadline

Updated Category News Views 156

A Narrow Calendar Window Has Opened Intel holders have another legal deadline to put on the fridge, and this one is not a casual housekeeping item. A securities class action has been filed in the Northern District of California on behalf of investors who bought or acquired Intel shares between July 23, 2026, and October 29, 2026. The deadline to seek appointment as lead...

Continue Reading
BreakBio's New CSO Adds Vaccine Trial Credibility in Cancer

Updated Category News Views 144

Personalized cancer vaccines have no shortage of grand promises; seasoned clinical operators are the rarer commodity. That is why BreakBio's appointment of Dr. Greg Lizée as chief scientific officer deserves a closer look, even if nobody should confuse an executive hire with clinical validation. BreakBio is private, its lead program remains in development, and cancer...

Continue Reading
SAP Execution Can Steady Operations Beyond Spreadsheets

Updated Category News Views 114

Spreadsheets breed little kingdoms, and SAP is often left outside the gate. That is the operational mess Martin Rowan, managing partner at Reveal USA, Inc. in Naperville, is taking aim at in a Nov. 19, 2026 HelloNation feature. His central point is not terribly glamorous, but it is dead right: a company gets less stable when it uses SAP to explain yesterday's results...

Continue Reading
Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 193

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
AI Shopping Answers Are Becoming Retail's New Shelf

Updated Category News Views 24

Retail’s front door is quietly being moved by a machine, and plenty of big chains appear to be staring at the old entrance. Bain’s latest work lands on an uncomfortable point: owning market share does not guarantee a retailer gets named when an AI assistant answers a shopper’s question. That ought to rattle management teams more than the usual holiday-season...

Continue Reading
Baker Tilly Breach Raises Hard Questions on Vendor Risk

Updated Category News Views 121

A Quiet Vendor Failure Can Become a Loud Problem Tax files are not ordinary customer records, and that is why this reported Baker Tilly Advisory Group breach deserves more than the usual shrug people give cyber incidents. Names and addresses are bad enough; the potential exposure of Social Security numbers and other sensitive information turns a systems failure into a...

Continue Reading

Top 5 Most Recently Viewed Articles

Massimo Group Sees Growth Amid Challenges in Q3 2024

Updated Category News Views 362

Massimo Group Reports Solid Year-to-Date Revenue Growth Massimo Group (NASDAQ: MAMO) has shared encouraging financial results for the year so far, showcasing a remarkable 20.8% increase in revenue year-over-year (YoY), totaling $91.2 million. This positive trend is largely attributed to the company's innovative production, product enhancements, and effective sales...

Continue Reading
Earnings Preview: What to Expect from Dayforce's Q2 Results

Updated Category News Views 246

Anticipation for Dayforce's Upcoming Earnings Dayforce (NYSE: DAY) is gearing up for its quarterly earnings announcement, which is scheduled for a Wednesday. Investors are eagerly awaiting insights into the company's performance, particularly focusing on earnings surpassing estimates and positive guidance for future quarters. Analyst Expectations Industry analysts predict...

Continue Reading
AutoRABIT CodeScan Enhances Security for AI-Driven Code

Updated Category News Views 71

The Essential Role of AutoRABIT CodeScan in AI Security As artificial intelligence shapes the landscape of software development, it brings both exciting innovations and significant security challenges. AutoRABIT CodeScan stands out as a crucial tool designed to address these vulnerabilities, helping developers work safely with AI-generated code. Exploring the Risks of AI...

Continue Reading
Mythos AI Breaks New Ground in Autonomous Shipping Navigation

Updated Category News Views 240

Mythos AI Achieves Milestone in Autonomous Navigation In a groundbreaking achievement, Mythos AI has successfully surpassed 11,000 miles of fully autonomous navigation, marking a significant advancement in shipping technology. The company's AI-driven navigation system not only exceeds military-grade capabilities in safety and operational efficiency but also sets a new...

Continue Reading
Explore the Rich Tapestry of Michigan's Harvest Season

Updated Category News Views 218

Experience Michigan's Harvest Season As autumn settles in, Michigan transforms into a breathtaking landscape filled with vibrant colors and rich traditions. This time of year, the state's famous agriculture thrives, creating an atmosphere that beckons travelers to experience the harvest season to the fullest. From golden fields of corn to sprawling orchards full of ripe...

Continue Reading